Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.
van der Sluis TC, Beyrend G, van der Gracht ETI, Abdelaal T, Jochems SP, Belderbos RA, Wesselink TH, van Duikeren S, van Haften FJ, Redeker A, Ouboter LF, Beyranvand Nejad E, Camps M, Franken KLMC, Linssen MM, Hohenstein P, de Miranda NFCC, Mei H, Bins AD, Haanen JBAG, Aerts JG, Ossendorp F, Arens R. van der Sluis TC, et al. Cell Rep Med. 2023 Mar 21;4(3):100939. doi: 10.1016/j.xcrm.2023.100939. Epub 2023 Feb 15. Cell Rep Med. 2023. PMID: 36796366 Free PMC article.
Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.
van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, van de Water B, Arens R, van der Burg SH, Melief CJ. van der Sluis TC, et al. Among authors: van duikeren s, van de water b, van der burg sh. Clin Cancer Res. 2015 Feb 15;21(4):781-94. doi: 10.1158/1078-0432.CCR-14-2142. Epub 2014 Dec 12. Clin Cancer Res. 2015. PMID: 25501579
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.
Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH. Welters MJ, et al. Among authors: van duikeren s, van meir h, van der burg sh, van der sluis tc, van ham vj, van poelgeest mi. Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307. Sci Transl Med. 2016. PMID: 27075626 Clinical Trial.
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.
Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA, Melief CJ, van der Burg SH, Arens R. Beyranvand Nejad E, et al. Among authors: van duikeren s, van veelen pa, van der burg sh, van der sluis tc. Cancer Res. 2016 Oct 15;76(20):6017-6029. doi: 10.1158/0008-5472.CAN-16-0881. Epub 2016 Aug 28. Cancer Res. 2016. PMID: 27569212
Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG, Willems MMJHP, Khan S, van der Sluis TC, Kleinovink JW, Camps MGM, van der Marel GA, Filippov DV, Melief CJM, Ossendorp F. Zom GG, et al. Among authors: van der sluis tc. J Immunother Cancer. 2018 Dec 12;6(1):146. doi: 10.1186/s40425-018-0455-2. J Immunother Cancer. 2018. PMID: 30541631 Free PMC article.
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy.
Beyranvand Nejad E, Labrie C, Abdulrahman Z, van Elsas MJ, Rademaker E, Kleinovink JW, van der Sluis TC, van Duikeren S, Teunisse AFAS, Jochemsen AG, Oosting J, de Miranda NFCC, Van Hall T, Arens R, van der Burg SH. Beyranvand Nejad E, et al. Among authors: van der sluis tc. J Immunother Cancer. 2020 Sep;8(2):e001326. doi: 10.1136/jitc-2020-001326. J Immunother Cancer. 2020. PMID: 32873723 Free PMC article.
19 results